See more : Coro Global Inc. (CGLO) Income Statement Analysis – Financial Results
Complete financial analysis of Echo Therapeutics, Inc. (ECTE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Echo Therapeutics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Qingdao Daneng Environmental Protection Equipment Co., Ltd. (688501.SS) Income Statement Analysis – Financial Results
- Planet Green Holdings Corp. (PLAG) Income Statement Analysis – Financial Results
- KB Financial Group Inc. (KB) Income Statement Analysis – Financial Results
- Enprise Group Limited (ENS.NZ) Income Statement Analysis – Financial Results
- Artisan Acquisition Corp. (ARTAU) Income Statement Analysis – Financial Results
Echo Therapeutics, Inc. (ECTE)
About Echo Therapeutics, Inc.
Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. It is developing continuous glucose monitoring (CGM) system, a needle-free wireless continuous glucose monitoring system in a hospital setting in the European Union. The company has a licensing agreement with Ferndale Pharma Group, Inc. to develop, manufacture, distribute, and market devices for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community. In addition, it has a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell CGM to medical facilities and individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989 and is headquartered in Iselin, New Jersey.
| Metric | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 57.32K | 27.60K | 5.12K | 447.21K | 428.46K | 1.33M | 0.00 | 57.95K | 175.66K | 33.57K | 1.50M | 0.00 | 3.81M | 120.97K | 5.03K | 9.30M | 7.10M | 3.60M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.56K | 251.48K | 16.68K | 0.00 | 0.00 | 1.42M | 262.78K | 1.37M | 4.20M | 3.70M | 2.00M |
| Gross Profit | 0.00 | 57.32K | 27.60K | 5.12K | 447.21K | 428.46K | 1.33M | 0.00 | 56.40K | -75.82K | 16.89K | 1.50M | 0.00 | 2.39M | -141.82K | -1.37M | 5.10M | 3.40M | 1.60M |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 97.32% | -43.16% | 50.31% | 100.00% | 0.00% | 62.80% | -117.24% | -27,214.35% | 54.84% | 47.89% | 44.44% |
| Research & Development | 2.79M | 4.96M | 11.30M | 8.67M | 3.80M | 2.58M | 2.81M | 3.19M | 8.30M | 3.79M | 3.04M | 2.27M | 1.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.33M | 7.42M | 8.37M | 6.37M | 4.91M | 2.76M | 3.05M | 3.74M | 4.60M | 2.06M | 2.42M | 1.74M | 2.21M | 2.18M | 2.09M | 292.24K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.33M | 7.42M | 8.37M | 6.37M | 4.91M | 2.76M | 3.05M | 3.74M | 4.60M | 2.06M | 2.42M | 1.74M | 2.21M | 2.18M | 2.09M | 292.24K | 0.00 | 0.00 | 0.00 |
| Other Expenses | 521.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.16M | 1.38M | 4.30M | 2.70M | 1.20M |
| Operating Expenses | 7.64M | 12.38M | 19.66M | 15.05M | 8.70M | 5.34M | 5.86M | 6.93M | 12.90M | 5.85M | 5.46M | 4.01M | 4.19M | 2.18M | 3.25M | 1.68M | 4.30M | 2.70M | 1.20M |
| Cost & Expenses | 7.64M | 12.38M | 19.66M | 15.05M | 8.70M | 5.34M | 5.86M | 6.93M | 12.90M | 6.10M | 5.48M | 4.01M | 4.19M | 3.59M | 3.51M | 302.18K | 8.50M | 6.40M | 3.20M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 15.34K | 3.55M | 3.90M | 959.86K | 13.93K | 37.55K | 331.50K | 1.05M | 435.90K | 18.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 300.00K | 0.00 | 100.00K |
| Depreciation & Amortization | 521.86K | 392.73K | 391.60K | 145.16K | 47.92K | 109.41K | 158.62K | 191.72K | 151.57K | 239.42K | 156.90K | 154.93K | 147.46K | 295.59K | 1.16M | 1.38M | 1.30M | 900.00K | 400.00K |
| EBITDA | -21.66M | -11.01M | -14.78M | -11.23M | -9.97M | -4.00M | -10.47M | -9.35M | -12.64M | -5.48M | -5.20M | -2.32M | -4.01M | 2.67M | -3.71M | 1.30M | 1.80M | 600.00K | -100.00K |
| EBITDA Ratio | 0.00% | -19,215.37% | -53,535.63% | -219,320.08% | -2,228.87% | -933.54% | -785.93% | 0.00% | -21,807.37% | -3,119.34% | -15,502.10% | -154.97% | 0.00% | 70.09% | -3,070.86% | 25,863.82% | 19.35% | 8.45% | -2.78% |
| Operating Income | -7.64M | -12.32M | -19.64M | -15.04M | -8.25M | -4.91M | -4.53M | -6.93M | -12.85M | -5.93M | -5.45M | -2.51M | -4.19M | 213.22K | -3.39M | -297.14K | 800.00K | 700.00K | 400.00K |
| Operating Income Ratio | 0.00% | -21,492.86% | -71,146.62% | -293,807.77% | -1,845.81% | -1,146.07% | -340.15% | 0.00% | -22,164.91% | -3,373.87% | -16,226.34% | -167.07% | 0.00% | 5.60% | -2,805.56% | -5,906.26% | 8.60% | 9.86% | 11.11% |
| Total Other Income/Expenses | -14.56M | -2.64M | 569.07K | 2.71M | -1.77M | 799.69K | -6.10M | -2.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.16M | -1.64M | 53.34K | -600.00K | -1.00M | -900.00K |
| Income Before Tax | -22.19M | -14.96M | -19.07M | -12.33M | -10.02M | -4.11M | -10.63M | -9.57M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.37M | -5.03M | -243.81K | 200.00K | -300.00K | -500.00K |
| Income Before Tax Ratio | 0.00% | -26,096.29% | -69,084.77% | -240,906.58% | -2,240.66% | -959.43% | -797.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 62.32% | -4,158.14% | -4,846.07% | 2.15% | -4.23% | -13.89% |
| Income Tax Expense | 3.42K | 4.00K | 4.47M | 3.67M | -1.75M | 837.24K | -5.77M | -1.59M | 435.90K | 18.29K | 0.00 | 0.00 | 0.00 | 1.37M | -1.86M | -66.00K | 100.00K | -200.00K | -800.00K |
| Net Income | -22.20M | -14.96M | -19.07M | -12.33M | -10.03M | -4.15M | -10.96M | -10.60M | -13.23M | -5.74M | -5.36M | -2.48M | -4.16M | 1.00M | -3.02M | -16.92K | 100.00K | -100.00K | -600.00K |
| Net Income Ratio | 0.00% | -26,103.27% | -69,084.77% | -240,906.58% | -2,242.70% | -967.84% | -822.73% | 0.00% | -22,821.08% | -3,266.05% | -15,969.56% | -165.30% | 0.00% | 26.37% | -2,497.65% | -336.24% | 1.08% | -1.41% | -16.67% |
| EPS | -1.98 | -1.22 | -2.28 | -3.12 | -3.45 | -1.43 | -4.92 | -5.69 | -11.24 | -25.84 | -31.97 | -40.23 | -67.44 | 31.18 | -93.11 | -0.58 | 4.00 | -5.17 | -31.00 |
| EPS Diluted | -1.98 | -1.22 | -2.28 | -3.12 | -3.45 | -1.43 | -4.92 | -5.69 | -11.24 | -25.84 | -31.97 | -40.23 | -67.44 | 31.03 | -93.11 | -0.58 | 4.00 | -5.17 | -31.00 |
| Weighted Avg Shares Out | 11.23M | 12.31M | 8.36M | 3.96M | 2.90M | 2.90M | 2.23M | 1.86M | 1.18M | 222.05K | 167.64K | 61.63K | 61.63K | 32.21K | 32.45K | 29.16K | 25.00K | 19.36K | 19.36K |
| Weighted Avg Shares Out (Dil) | 11.23M | 12.31M | 8.36M | 3.96M | 2.90M | 2.90M | 2.23M | 1.86M | 1.18M | 222.05K | 167.64K | 61.63K | 61.63K | 32.36K | 32.45K | 29.26K | 25.00K | 19.36K | 19.36K |
Source: https://incomestatements.info
Category: Stock Reports